PSTV
Plus Therapeutics·NASDAQ
--
--(--)
--
--(--)
0.97 / 10
Underperform
The company shows poor fundamentals (1.0/10). Positive drivers: Current assets turnover ratio and Fixed assets turnover ratio, balanced by issues in Net profit / Total profit (%) and Gross profit margin (%). This supports a defensive investment view.
Analysis Checks(3/5)
Inventory turnover ratio
Value34.43
Score2/3
Weight191.46%
1M Return-2.63%
Value34.43
Score2/3
Weight191.46%
1M Return-2.63%
Current assets turnover ratio
Value0.01
Score2/3
Weight-88.34%
1M Return1.15%
Value0.01
Score2/3
Weight-88.34%
1M Return1.15%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Gross profit margin (%)
Value100.00
Score1/3
Weight38.92%
1M Return-0.54%
Value100.00
Score1/3
Weight38.92%
1M Return-0.54%
Fixed assets turnover ratio
Value0.16
Score3/3
Weight-64.36%
1M Return0.86%
Value0.16
Score3/3
Weight-64.36%
1M Return0.86%
Inventory turnover ratio
Value34.43
Score2/3
Weight191.46%
1M Return-2.63%
Value34.43
Score2/3
Weight191.46%
1M Return-2.63%
Gross profit margin (%)
Value100.00
Score1/3
Weight38.92%
1M Return-0.54%
Value100.00
Score1/3
Weight38.92%
1M Return-0.54%
Current assets turnover ratio
Value0.01
Score2/3
Weight-88.34%
1M Return1.15%
Value0.01
Score2/3
Weight-88.34%
1M Return1.15%
Fixed assets turnover ratio
Value0.16
Score3/3
Weight-64.36%
1M Return0.86%
Value0.16
Score3/3
Weight-64.36%
1M Return0.86%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Value100.00
Score0/3
Weight22.32%
1M Return-0.30%
Is PSTV fundamentally strong?
- PSTV scores 0.97/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -391.33% net margin, -2.25 P/E ratio, 9.17 P/B ratio, and 63.89% earnings growth, these metrics solidify its Underperform investment rating.
